In 2025, Boundless Bio advanced its strategy focusing on innovative therapies targeting oncogene amplified cancers, particularly through its selective CHK1 inhibitor BBI-355 and kinesin degrader BBI-940. The company undertook significant workforce reductions and leadership restructuring to sharpen its focus on combination therapies. Financially, while operating and net losses narrowed year-over-year, the company sustains strong liquidity positioned to fund clinical proof-of-concept milestones anticipated in the near term. Key risks persist from early-stage development challenges and competitive dynamics in oncology.